Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec;87(24):13892-9.
doi: 10.1128/JVI.02448-13. Epub 2013 Sep 25.

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

Affiliations

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

Kei Ohnuma et al. J Virol. 2013 Dec.

Abstract

We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

PubMed Disclaimer

Figures

Fig 1
Fig 1
CD26 expression and binding of MERS-CoV S1-Fc in parental Jurkat cells and CD26 Jurkat transfectants. (A) Representative histograms showing results of staining of Jurkat cells stably transfected with the full-length human CD26 (JKT-hCD26WT) or vector control (JKT-Mock) with Alexa Fluor 488-labeled anti-CD26 MAb 2F9 (5 μg/ml; black).Gray histograms show results of staining with an isotype control (Alexa Fluor 488-labeled mouse IgG [msIgG-488]; 5 μg/ml). Results representative of three different experiments are shown. (B) Representative histograms showing results of staining with Alexa Fluor-labeled MERS-CoV S1-Fc (5 μg/ml; black) using JKT-Mock or JKT-hCD26WT. Gray histograms show staining with Alexa Fluor 488-labeled recombinant human Fc (Fc-488) as an isotype control. Results representative of three different experiments are shown.
Fig 2
Fig 2
Anti-CD26 MAb 2F9 inhibits binding of MERS-CoV S1-Fc. (A) Representative histograms showing results of staining with MERS-CoV S1-Fc in the presence of various clones of anti-CD26 MAbs or control mouse IgG (left). JKT-hCD26WT cells were incubated with the indicated anti-CD26 MAb (mouse MAb 4G8, 1F7, 14D10, 2F9, 16D4B, or 9C11 or humanized MAb YS110) (red) or control IgG (black) (each 10 μg/ml) for 30 min at 4°C. After being washed, cells were stained with Alexa Fluor 488-labeled MERS-CoV S1-Fc (5 μg/ml). Gray histograms show results of staining with Fc-488 as an isotype control. Mean fluorescence intensities (MFI) of Alexa Fluor 488-labeled MERS-CoV S1-Fc are indicated in the bar graph (right). Results representative of three different experiments are shown as mean MFI. Error bars indicate standard errors of the means (SEMs) (two-tailed Student's t test; * or **, P < 0.05 versus control IgG). (B to D) MFI of staining with Alexa Fluor 488-labeled MERS-CoV S1-Fc in the presence of various concentrations of the anti-CD26 MAb 2F9 (B), 1F7 (C), or YS110 (D) (red) or control msIgG (black). JKT-hCD26WT cells were incubated with the indicated concentrations of the anti-CD26 MAbs or control IgG for 30 min at 4°C. After being washed, cells were stained with Alexa Fluor 488-labeled MERS-CoV S1-Fc (5 μg/ml). Results of three different experiments are shown as mean MFI ± SEMs (two-tailed Student's t test; *, P < 0.05 versus corresponding control IgG). The black and red bars at 0 μg/ml of preincubated control IgG or anti-CD26 MAbs were plotted using the same data.
Fig 3
Fig 3
Preincubation with MERS-CoV S1-Fc partially inhibits binding of MERS-CoV S1-Fc. (A) Representative histograms showing results of staining with MERS-CoV S1-Fc in the presence of various concentrations of unlabeled MERS-CoV S1-Fc or control Fc (left). JKT-hCD26WT cells were incubated with the indicated concentrations of unlabeled MERS-CoV S1-Fc (dashed) or control Fc (black) for 30 min at 4°C. After being washed, cells were stained with Alexa Fluor 488-labeled MERS-CoV S1-Fc (5 μg/ml). Gray histograms show staining with the isotype control (Fc-488). MFI of Alexa Fluor 488-labeled MERS-CoV S1-Fc are indicated in the bar graph (right). Results representative of three different experiments are shown as mean MFI. Error bars indicate SEMs (two-tailed Student's t test; *, P < 0.05 versus corresponding control Fc). The black and dark-gray bars at 0 μg/ml of preincubated MERS-CoV S1-Fc or control Fc were plotted using the same data. (B) Representative histograms showing staining with the anti-CD26 MAb 14D10 in the presence of various concentrations of MERS-CoV S1-Fc or control Fc. The experiments were conducted as for panel A. Gray histograms show staining with the isotype control (msIgG-488).
Fig 4
Fig 4
Binding regions of ADA (adenosine deaminase 1) in CD26 are involved in the binding of MERS-CoV S1-Fc to human CD26. (A) Representative histograms showing results of the binding of ADA to JKT-Mock (left) or JKT-hCD26WT (right). JKT-Mock or JKT-hCD26WT was incubated with 10 μg/ml of Alexa Fluor 488-labeled ADA or ADA2 (CECR1) as a fluorescence control. Data are representative of three independent experiments, with similar results being obtained. (B) MFI for staining with Alexa Fluor 488-labeled ADA in the presence of various concentrations of the anti-CD26 MAb 2F9 (dark gray), 1F7 (light gray), YS110 (gray), or control msIgG (black). JKT-hCD26WT cells were incubated with the indicated concentrations of anti-CD26 MAbs or control IgG for 30 min at 4°C. After being washed, cells were stained with Alexa Fluor 488-labeled ADA (10 μg/ml). Alexa Fluor 488-labeled ADA2 was used as a fluorescence control, with MFI being <10. Results representative of three different experiments are shown as mean MFI. Error bars indicate SEMs (two-tailed Student's t test; *, P < 0.05 versus corresponding control IgG). (C, panel a) Representative histograms showing results for binding of ADA (left) or the anti-CD26-MAb 14D10 (right) to Jurkat cells stably transfected with human CD26 with a deletion of the ADA binding region (JKT-hCD26-ADA). Gray histograms show Alexa Fluor 488-labeled ADA2 or msIgG-488 as a fluorescence control. (b) Representative histograms showing results for staining with MERS-CoV S1-Fc of JKT-hCD26-ADA. JKT-hCD26-ADA cells were stained with Alexa Fluor 488-labeled MERS-CoV S1-Fc (black) at the indicated concentrations. Gray histograms show results for staining with Fc-488 as an isotype control. Data are representative of three independent experiments, with similar results being obtained.
Fig 5
Fig 5
2F9 fully inhibits binding to MERS-CoV S1-Fc of CD26 in the presence of exogenous ADA. (A and B) Representative histograms showing results for staining with MERS-CoV S1-Fc (A) or 2F9 (B) in the presence of various concentrations of exogenous ADA (dashed) or PBS (black) as a solvent control (vehicle) (left). JKT-hCD26WT cells were incubated with the indicated concentrations of exogenous ADA or corresponding concentrations of diluted PBS for 30 min at 37°C. After being washed, cells were stained with Alexa Fluor 488-labeled MERS-CoV S1-Fc or 2F9 (each 5 μg/ml). Gray histograms show results for staining with Fc-488 or msIgG-488 as an isotype control. MFI for Alexa Fluor 488-labeled MERS-CoV S1-Fc or 2F9 are indicated in the bar graphs (right). Results representative of three different experiments are shown as mean MFI. Error bars indicate SEMs (two-tailed Student's t test; *, P < 0.05 versus corresponding vehicle). The black and gray bars at 0 μg/ml of preincubated ADA or vehicle were plotted using the same data. (C) Representative histograms showing results for staining with MERS-CoV S1-Fc in the presence of various concentrations of exogenous ADA with the addition of 2F9 (dashed). JKT-hCD26WT cells were incubated with the indicated concentrations of exogenous ADA or corresponding concentrations of diluted PBS for 30 min at 37°C, followed by additional incubation with 2F9 (10 μg/ml) or control msIgG (10 μg/ml) for 30 min at 4°C. After being washed, cells were stained with Alexa Fluor 488-labeled MERS-CoV S1-Fc (5 μg/ml). The dashed histogram in the left panel shows results for staining with MERS-CoV S1-Fc in the presence of PBS with the addition of control msIgG. Gray histograms show staining with Fc-488 as an isotype control. Results representative of three different experiments are shown.
Fig 6
Fig 6
Characterization of regions of CD26 that bind to MERS-CoV S1-Fc through the use of CD26 deletion or human/rat swap mutants. Representative histograms show results for staining for MERS-CoV S1-Fc, 2F9, or YS110. CD26 cDNAs with full-length human CD26 (a), the indicated deletion (b through f), human/rat (H/R) swap mutants (h through j), or vector control (g) were cotransfected with GFP-expressing plasmids to COS-1 cells. After 24 h of transfection, cells were stained with Alexa Fluor 647-labeled MERS-CoV S1-Fc, 2F9, or YS110 (each 5 μg/ml). Gray histograms show results of staining with Fc-647 or msIgG-647 as an isotype control. The histograms for Alexa Fluor 647 were obtained by gating for GFP-positive cells among all acquired cells. Results of three different experiments are shown as percent positive cells in full-length CD26 (bar graphs, bottom). Error bars indicate SEMs (two-tailed Student's t test; *, P < 0.05 versus mock; **, P < 0.05 versus corresponding mutants; ***, P < 0.05 versus corresponding rat full-length CD26). Vertical dashed lines in the histograms indicate borders between negative and positive intensities. In the diagrams of CD26, TM indicates a transmembrane region of human CD26, and amino acids (aa) derived from human (H) or rat (R) are represented in white or dark-gray boxes, respectively.
Fig 7
Fig 7
Schematic diagram of human CD26 profiling the predicted contact areas of anti-CD26 MAbs 2F9, 1F7, YS110, and MERS-CoV S1. 2F9 recognizes between 248 and 449 aa, including the ADA binding regions, and 1F7 and YS110 recognize between 248 and 358 aa, excluding the ADA binding regions. MERS-CoV-contacting residues of human CD26 are indicated by asterisks; information was obtained from recently published data (17, 18). TM indicates a transmembrane region of human CD26 (black box), and the extracellular domain of CD26 is located at the C-terminal residues of TM.
Fig 8
Fig 8
Inhibition of MERS-CoV infection by the anti-CD26 MAb 2F9. Huh-7 cells were preincubated with normal mouse IgG, various anti-CD26 MAbs (4G8, 1F7, 2F9, 16D4B, 9C11, or 14D10), humanized anti-CD26 MAb (YS110), or anti-CD26 goat polyclonal antibody (pAb) at a concentration of 40 μg/ml for 0.5 h prior to MERS-CoV virus inoculation (1 h), all at room temperature. Mock-incubated cells (control) were used as controls. Following incubation at 37°C for 8 h, infected cells were detected by immunofluorescence using anti-SARS-CoV NSP4 antibodies that are cross-reactive for MERS-CoV, and infection was quantified as the number of anti-SARS-CoV NSP4-positive cells. Two independent experiments were performed, and data from one representative experiment are shown. Error bars indicate SEMs (two-tailed Student's t test; *, **, or ***, P < 0.05 versus control.

Similar articles

Cited by

References

    1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367:1814–1820 - PubMed
    1. Enserink M. 2013. New coronavirus reveals some of its secrets. Science 340:17–18 - PubMed
    1. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish Z, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. 2013. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J. Virol. 87:7790–7792 - PMC - PubMed
    1. CDC 2013. Update: severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS-CoV)—worldwide, 2012-2013. MMWR Morb. Mortal. Wkly. Rep. 62:480–483 - PMC - PubMed
    1. WHO 2013. Novel coronavirus infection—update. http://www.who.int/csr/don/2013_09_17_ncov/en/index.html

Publication types

MeSH terms